Reprocell USA has secured a contract from Lantern Pharma to provide support for a Phase II study of LP-300 for advanced non-small cell lung cancer (NSCLC).
The trial entitled ‘A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)’ is designed to evaluate LP-300’s effect in combination with standard-of-care chemotherapy on the progression-free and overall survival of never smoker patients with NSCLC.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In a total of 90 patients, two thirds will receive LP-300 with chemotherapy and a third will receive chemotherapy alone.
The study is planned to be initiated at five clinical trial sites with over 12 locations in the US.
Northwest Oncology, Gabrail Cancer Center, Texas Oncology, Cancer and Blood Specialty Clinic, and New York Cancer and Blood Specialists will be involved in the study.
As part of the study, Reprocell will process patient samples and store biomaterial from patients as well as produce Specimen Collection Kits.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition, it will archive pathology formalin fixed paraffin embedded samples, and associated H&E-stained slides from selected patients.
Reprocell will also provide cell free DNA isolation from plasma, genomic DNA and/or RNA from the buffy coat fraction.
All pathology materials and biomaterials on-site will be retained by Reprocell until needed for Lantern Pharma.
Reprocell CEO Rama Modali said: “We are pleased to support Lantern Pharma in the Harmonic clinical trial. We believe that our capabilities in building kits, managing shipments to and from clinical sites and processing the bio samples will help Lantern Pharma in successfully conducting this trial.”
